Deucravacitinib for the Treatment of Palmoplantar Pustulosis

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT05710185
Phase
PHASE4
Status
Terminated

Conditions

  • Palmoplantar Pustulosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

A prospective, single-arm, open-label trial of deucravacitinib 6 mg daily in patients with PPP. All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.

Key Dates

Start date
Jul 1, 2023
Status verified
Mar 2026
Primary completion
Dec 1, 2024
Completion
Jan 31, 2025

Study Design

Enrollment
3 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Subjects with Palmoplantar pustulosis
    All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.

Primary Outcome Measure

Proportion of Participants Who Achieve a ppPASI-50 Response, or at Least 50% Improvement in ppPASI Score [ Time Frame: 16 weeks ]

Locations (2)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02115-
University of PennsylvaniaPhiladelphiaPennsylvania19104-

Related coverage on Hipa.ai

Find similar trials in Boston, MA

By research site
Brigham and Women's Hospital· Boston, MAUniversity of Pennsylvania· Philadelphia, PA

Related Studies